CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 2024—Sekisui Diagnostics has received emergency use authorization for its Osom Flu SARS-CoV-2 Combo test for use in professional and home testing settings. The lateral flow immunochromatographic assay is intended for the qualitative detection and differentiation of influenza A and B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen. The test is for in vitro diagnostic use.
Sekisui Diagnostics, 781-652-7800